...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Hematology >FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment
【24h】

FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment

机译：FLAGIDA-lite是治疗急性髓性白血病或难治性贫血且母细胞过多2的70至80岁患者的有效方案，可作为门诊治疗方案

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We investigated a FLAGIDA-lite protocol (fludarabine 40 mg/m 2/d orally days 1-5, cytarabine 20 mg/m 2/d subcutaneously days 1-5, G-CSF 300 μg/d subcutaneously days 1-5, and idarrubicin 15 mg/m 2/d orally days 1-3) in 38 consecutive patients older than 70 years of age with acute myeloid leukemia (32 patients) or refractory anemia with excess blasts-2 (six patients) and no prior therapy. Seventy-nine percent had intermediate/unfavorable karyotype and 79% had a high comorbidity. Overall response was 55% [complete response (CR) 47%] and 37% were refractory. CR rate was 52% in patients between 71 and 79 years of age and 38% in patients 80 years or older. The 4-week induction mortality was 16% (8% in patients between 70 and 79 years of age and 32% in patients 80 years or older). Overall survival (OS) at 3 years was 22% (31.3% in patients between 70 and 79 years and 15.4% in patients 80 years or older). Relapse-free survival (RFS) at 3 years was 15%. A total of 65 cycles (47 as induction and 18 as consolidation) were administered, 46 of them (70%) in an outpatient setting. In summary, this FLAGIDA-lite protocol is an effective and well-tolerated option for patients between the ages of 70 and 79 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is usually feasible as outpatient treatment, but is not beneficial for most patients 80 years or older.
机译：我们调查了FLAGIDA-lite方案（氟达拉滨40 mg / m 2 / d口服，第1-5天，阿糖胞苷20 mg / m 2 / d，皮下注射，第1-5天，G-CSF 300μg/ d皮下注射，第1-5天，以及连续38例年龄在70岁以上的急性髓样白血病（32例）或难治性贫血伴有过量blasts-2的难治性贫血（6例患者），未接受任何治疗，连续1-3天口服idarrubicin 15 mg / m 2 / d。 79％具有中等/不利的核型，79％具有高合并症。总体缓解率为55％[完全缓解（CR）47％]，其中37％为难治性。 71至79岁患者的CR率为52％，80岁以上患者的CR为38％。 4周的诱导死亡率为16％（70至79岁的患者为8％，80岁或80岁以上的患者为32％）。 3年总生存率（OS）为22％（70至79岁患者为31.3％，80岁或80岁以上患者为15.4％）。 3年无复发生存率（RFS）为15％。总共进行了65个周期（诱导为47个周期，巩固为18个周期），其中46个周期（70％）在门诊患者中进行。总之，对于患有急性髓细胞性白血病或具有过量母细胞2的难治性贫血的70至79岁的患者，这种FLAGIDA-lite方案是一种有效且耐受良好的选择，通常可作为门诊治疗，但无益对于大多数80岁以上的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号